Paper40702000
RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.
Wang Z and 7 others. Cell Death Discov, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. Papers, record 40702000. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40702000
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36941989 | Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells. | Open Med (Wars) | 2023 | https://conductscience.org/library/papers/36941989 | PubMed |
| 2 | 35615981 | Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/35615981 | PubMed |
| 3 | 37575948 | Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma. | Natl Sci Rev | 2023 | https://conductscience.org/library/papers/37575948 | PubMed |
| 4 | 35679518 | In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies. | Cancer Immunol Res | 2022 | https://conductscience.org/library/papers/35679518 | PubMed |
| 5 | 37804830 | Arginine reprograms metabolism in liver cancer via RBM39. | Cell | 2023 | https://conductscience.org/library/papers/37804830 | PubMed |
| 6 | 35490918 | RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35490918 | PubMed |
| 7 | 35292350 | Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. | J Hepatol | 2022 | https://conductscience.org/library/papers/35292350 | PubMed |
| 8 | 37772582 | RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression. | Anticancer Res | 2023 | https://conductscience.org/library/papers/37772582 | PubMed |
| 9 | 37067402 | A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma. | Mol Carcinog | 2023 | https://conductscience.org/library/papers/37067402 | PubMed |
| 10 | 37726886 | Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. | Cell Adh Migr | 2023 | https://conductscience.org/library/papers/37726886 | PubMed |
| 11 | 37813165 | An intricate rewiring of cancer metabolism via alternative splicing. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/37813165 | PubMed |
| 12 | 33794886 | Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma. | Cancer Cell Int | 2021 | https://conductscience.org/library/papers/33794886 | PubMed |
| 13 | 37715846 | Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma. | Abdom Radiol (NY) | 2023 | https://conductscience.org/library/papers/37715846 | PubMed |
| 14 | 37597404 | Alternative splicing events and function in the tumor microenvironment: New opportunities and challenges. | Int Immunopharmacol | 2023 | https://conductscience.org/library/papers/37597404 | PubMed |
| 15 | 32497093 | Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma. | PLoS One | 2020 | https://conductscience.org/library/papers/32497093 | PubMed |
| 16 | 34171309 | Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. | Cell | 2021 | https://conductscience.org/library/papers/34171309 | PubMed |
| 17 | 39802808 | PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release. | JHEP Rep | 2025 | https://conductscience.org/library/papers/39802808 | PubMed |
| 18 | 36520054 | AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells. | FASEB J | 2023 | https://conductscience.org/library/papers/36520054 | PubMed |
| 19 | 29018272 | Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. | Nat Rev Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29018272 | PubMed |
| 20 | 34764464 | Immunotherapies for hepatocellular carcinoma. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34764464 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42623381 | Streptomyces-linked exercise gene networks orchestrate immune exclusion and determine immunotherapy response in hepatocellular carcinoma. | PLoS One | 2026 | https://conductscience.org/library/papers/42623381 | PubMed |
| 42620997 | AI-integrated single-cell multi-omics decodes the hepatocellular carcinoma metabolism-immune axis: a new strategy for precision therapeutic targeting. | Front Oncol | 2026 | https://conductscience.org/library/papers/42620997 | PubMed |
| 42292467 | Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292467 | PubMed |
| 42062247 | RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation. | Cell Death Discov | 2026 | https://conductscience.org/library/papers/42062247 | PubMed |
| 41986071 | Non-enzymatic Rnaseh2c orchestrates proliferating macrophage-driven immunosuppression and HCC progression via Cdk9 proliferation axis and CCL2/CCR2-mediated CD8+ Tex infiltration: a novel therapeutic paradigm with "Rnaseh2c-In1" inhibitor. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41986071 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CSAD | 51380 | PubTator's text mining | https://conductscience.org/library/genes/51380 | NCBI Gene |
| HACD3 | 51495 | PubTator's text mining | https://conductscience.org/library/genes/51495 | NCBI Gene |
| RBM17 | 84991 | PubTator's text mining | https://conductscience.org/library/genes/84991 | NCBI Gene |
| RUNX1 | 861 | PubTator's text mining | https://conductscience.org/library/genes/861 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40702000
GET https://conductscience.org/api/papers/v1/40702000/references?page=2